Assenagon Asset Management
OCUL icon

Assenagon Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Assenagon Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Hold
45,600
– – ﹤0.01% 1082
2026
Q1 		$386K Sell
45,600
-575,214
-93% -$5.48M ﹤0.01% 1025
2025
Q4 		$7.54M Buy
620,814
+575,214
+1,261% +$6.99M 0.01% 570
2025
Q3 		$533K Sell
45,600
-148,100
-76% -$1.77M ﹤0.01% 1045
2025
Q2 		$1.8M Sell
193,700
-148,100
-43% -$1.16M ﹤0.01% 802
2025
Q1 		$2.51M Buy
+341,800
New +$2.63M ﹤0.01% 691
2024
Q4 		– Sell
-2,825,756
Closed -$24.6M – 1419
2024
Q3 		$24.6M Buy
+2,825,756
New +$23.3M 0.05% 293
2022
Q1 		– Sell
-13,694
Closed -$95K – 1522
2021
Q4 		$95K Sell
13,694
-5,903
-30% -$45.8K ﹤0.01% 1397
2021
Q3 		$196K Sell
19,597
-77,417
-80% -$869K ﹤0.01% 1238
2021
Q2 		$1.38M Buy
97,014
+1,119
+1% +$17K ﹤0.01% 816
2021
Q1 		$1.57M Hold
95,895
– – 0.01% 773
2020
Q4 		$1.99M Buy
+95,895
New +$1.42M 0.01% 531

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management's OCUL Position: Q2 2026 in Review

Assenagon Asset Management held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 45,600 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #1082.

Assenagon Asset Management first reported a position in OCUL in Q4 2020 and has held it in 12 quarters since. The position peaked at $24.6M in Q3 2024. 261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Assenagon Asset Management held 45,600 shares of Ocular Therapeutix worth $448K as of Q2 2026.
  • Assenagon Asset Management left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #1082 holding.
  • Assenagon Asset Management first reported a position in Ocular Therapeutix in Q4 2020 and has held it in 12 quarters since.
  • Assenagon Asset Management's Ocular Therapeutix position peaked at $24.6M in Q3 2024.
  • 261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.